

KyooBe Tech unveils eFIT: a new era in safe and efficient Vaccine Manufacturing

Innovative solutions for pathogen inactivation in research and small-scale manufacturing

Leinfelden, Germany – June 28: KyooBe Tech, a pioneer in innovative pharmaceutical manufacturing technologies, today announced the launch of its new eFIT system. This technology uses low-energy electron irradiation to inactivate pathogens rapidly and continuously, providing an alternative to traditional methods in vaccine production.

The eFIT system is designed to address challenges in the biopharmaceutical industry by providing a chemical-free solution for pathogen inactivation.

eFIT significantly increases efficiency by accelerating production cycles compared to conventional chemical inactivation methods. This advancement allows for faster vaccine production, meeting the growing demands of the biopharmaceutical industry and enhancing the overall safety of the production process by eliminating the need for toxic chemicals such as formaldehyde. This chemical-free approach reduces potential health risks for workers and ensures a safer manufacturing environment. The system also improves the quality of vaccines by maintaining the integrity of surface proteins. This preservation is crucial for producing more effective vaccines that can elicit a robust immune response. Furthermore, the eFIT system offers remarkable versatility, making it suitable for inactivating various pathogens. Its adaptability allows it to be applied in multiple biopharmaceutical processes, providing a flexible solution for diverse manufacturing needs.

Dr. Andrea Traube, Chief Executive Officer at KyooBe Tech, commented, "The eFIT system represents a significant advancement in vaccine manufacturing. It not only enhances production speed and safety but also significantly improves product quality, setting a new standard in the industry."

The launch of eFIT follows extensive pilot testing and validation at an industrial scale. KyooBe Tech has optimized the system for commercial use, reducing its footprint while increasing production capacity to meet market demands. "We are thrilled to introduce eFIT to the market," said Daniel Becker, Head of Business Development eFIT at KyooBe Tech. "This technology has the potential to revolutionize vaccine manufacturing, making it faster, safer, and more cost-effective."

About KyooBe Tech GmbH

KyooBe Tech is an emerging technology provider with a strong focus on biotechnological applications. Founded in 2019 as a corporate start-up of the Bausch+Ströbel group, KyooBe Tech develops and commercializes innovative pharmaceutical production technologies. For more information about eFIT and KyooBe Tech's innovative solutions, visit www.kyooobe.tech.

Get in touch with us!

Daniel Becker

Head of Business Development eFIT
mail: Daniel.becker@kyooobe.tech
mobil: +491732902629